ClinConnect ClinConnect Logo
Search / Trial NCT00002538

Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers

Launched by GYNECOLOGIC ONCOLOGY GROUP · Jun 9, 2004

Trial Information

Current as of March 21, 2025

Completed

Keywords

Stage I Ovarian Epithelial Cancer Stage Ii Ovarian Epithelial Cancer Stage Iii Ovarian Epithelial Cancer Ovarian Undifferentiated Adenocarcinoma Ovarian Mixed Epithelial Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Clear Cell Cystadenocarcinoma Fallopian Tube Cancer Primary Peritoneal Cavity Cancer

ClinConnect Summary

OBJECTIVES: I. Determine the feasibility of laparoscopic staging of patients with incompletely staged ovarian, primary fallopian tube, and primary peritoneal cancers. II. Assess the adverse effects associated with this technique.

OUTLINE: Surgery. Laparoscopy with cytologic examination and lymph node sampling followed, if feasible, by surgical resection.

PROJECTED ACCRUAL: Up to 50 patients will be accrued over approximately 2 years. If more than 4 evaluable patients cannot complete surgery, the study will be closed.

Gender

FEMALE

Eligibility criteria

  • DISEASE CHARACTERISTICS: One of the following incompletely staged malignancies: Ovarian cancer of any cell type Primary fallopian tube carcinoma Primary peritoneal carcinoma No clinical evidence of metastases to abdominal organs, the adnexa, or retroperitoneal lymph nodes on CT with contrast or at prior abdominal surgery No metastases on chest x-ray No contraindications to laparoscopy, i.e.: No bowel obstruction No ileus No peritonitis No excessive obesity as indicated by a Quetelet Index over 35 (weight in kg/height in sqm) No diaphragmatic hernia on chest x-ray No grade 2 heart toxicity
  • PATIENT CHARACTERISTICS: Age: Adult Performance status: GOG 0 or 1 Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no more than 1.5 mg/dL AST no more than 3 times normal Renal: Creatinine no more than 2.0 mg/dL Other: No second malignancy except nonmelanomatous skin cancer Not pregnant
  • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or concomitant chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior or concomitant abdominal or pelvic radiotherapy Surgery: No prior retroperitoneal surgery No more than 10 weeks since initial abdominal surgery

Trial Officials

Nick M. Spirtos, MD

Study Chair

Women's Cancer Center - Palo Alto

About Gynecologic Oncology Group

The Gynecologic Oncology Group (GOG) is a leading clinical trial sponsor dedicated to advancing the understanding and treatment of gynecologic cancers. Comprising a network of experts in the field, GOG conducts rigorous, multi-institutional research to evaluate innovative therapeutic strategies and improve patient outcomes. Through its commitment to high-quality clinical trials, the organization aims to enhance the standard of care for women diagnosed with gynecologic malignancies, fostering collaborations with academic institutions and industry partners to translate scientific discoveries into effective treatments. GOG's mission emphasizes patient safety, ethical research practices, and the dissemination of findings to benefit the broader medical community.

Locations

Los Angeles, California, United States

Los Angeles, California, United States

Washington, District Of Columbia, United States

Washington, District Of Columbia, United States

Chicago, Illinois, United States

Minneapolis, Minnesota, United States

Durham, North Carolina, United States

Winston Salem, North Carolina, United States

Oklahoma City, Oklahoma, United States

Abington, Pennsylvania, United States

Palo Alto, California, United States

People applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials